Industry analyses and academic summaries characterize 2025 as a turning point for in‑vivo gene therapies, noting multiple clinical and preclinical advances that improved delivery, targeting and efficacy. Companies and research teams reported progress overcoming key barriers — tissue targeting, immune responses and scalable manufacturing — moving several programs closer to clinical validation. Reviews cite collective advances across viral vectors, nanoparticle platforms and novel payload designs that together accelerated translational momentum in the field.